Journal
LEUKEMIA & LYMPHOMA
Volume 46, Issue 1, Pages 1-10Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190400002202
Keywords
adoptive immunotherapy; EBV-associated malignancies
Categories
Funding
- NATIONAL CANCER INSTITUTE [P01CA094237, R01CA061384, U01CA061384] Funding Source: NIH RePORTER
- NCI NIH HHS [CA61384, P01 CA94237, P01 CA094237] Funding Source: Medline
Ask authors/readers for more resources
Latent Epstein-Barr virus (EBV) infection is associated with a diverse group of malignancies including Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma (NPC), and lymphoproliferative disease (LPD). EBV proteins expressed in these malignancies provide targets for the adoptive immunotherapy with antigen-specific cytotoxic T cells (CTL) and EBV-specific CTL have been used successfully for the prophylaxis and treatment of EBV-LPD post hematopoietic stem cell transplantation (HSCT). The clinical experience with EBV-specific CTL for other EBV-associated malignancies such as Hodgkin's disease and NPC is limited and the results obtained so far indicate that EBV-specific CTL are less effective than for EBV-LPD post HSCT. Decreased CTL efficacy most likely reflect immune evasion strategies by tumor cells such as down regulation of immunodominant EBV proteins and secretion of inhibitory cytokines. To overcome these immune evasion strategies a number of approaches have been developed including targeting CTL to subdominant EBV antigens and genetically modifying CTL to increase their potency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available